Last updated: September 2, 2026
Mipomersen sodium, marketed as Kynamro, was a commercial failure despite FDA approval for homozygous familial hypercholesterolemia (HoFH). Sanofi and Genzyme developed the drug for a small, high-risk population, but uptake remained limited because of weekly injections, liver-related monitoring, adverse-event concerns, high treatment cost, and competition from lomitapide, PCSK9 inhibitors, and LDL apheresis. Sanofi discontinued commercialization, and the FDA later withdrew approval at the company’s request for commercial reasons unrelated to safety or effectiveness.
What was mipomersen sodium approved to treat?
Mipomersen sodium is an antisense oligonucleotide that inhibits messenger RNA encoding apolipoprotein B-100, or apoB-100. ApoB-100 is required for the production of LDL and other atherogenic lipoproteins.
The FDA approved Kynamro on January 29, 2013, as an adjunct to lipid-lowering medicines and diet for patients with HoFH. The indication was limited to patients who had not achieved adequate LDL-cholesterol reduction with other treatments. The label did not position mipomersen as a general treatment for hypercholesterolemia.
| Attribute |
Mipomersen sodium |
| Brand |
Kynamro |
| Active ingredient |
Mipomersen sodium |
| Developer |
Ionis Pharmaceuticals, formerly Isis Pharmaceuticals |
| Commercial partner |
Genzyme, later Sanofi |
| Drug class |
Antisense oligonucleotide |
| Administration |
200 mg subcutaneous injection once weekly |
| FDA approval |
January 29, 2013 |
| Initial indication |
Homozygous familial hypercholesterolemia |
| FDA regulatory status |
Approval withdrawn at sponsor request |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
| Primary market |
United States |
| EU status |
No commercial European approval |
The FDA approval was based on LDL-cholesterol reduction rather than a demonstrated reduction in cardiovascular events. In the pivotal trial, mipomersen reduced LDL cholesterol by approximately 25% from baseline relative to placebo after 26 weeks. The label also warned about injection-site reactions, flu-like symptoms, elevations in liver transaminases, hepatic steatosis, and potential hepatotoxicity. (U.S. Food and Drug Administration, 2013)
How large was the commercial market for Kynamro?
The addressable population was structurally small. HoFH is an ultra-rare inherited disorder, with estimates commonly placing prevalence around one patient per million, although diagnosis rates vary by country and registry. The commercial market was constrained further by the availability of LDL apheresis and competing specialty medicines.
Kynamro’s list price was reported at approximately $176,000 per patient per year at launch. That price assumed sustained treatment adherence and reimbursement. Actual revenue was much lower than the theoretical market opportunity because patient identification, payer approval, treatment discontinuation, and physician adoption limited utilization.
The drug also had a difficult administration profile. Patients administered a weekly subcutaneous injection, often experienced injection-site reactions, and required liver monitoring. These burdens were significant in a chronic disease population that already had access to other intensive lipid-lowering approaches.
What was Kynamro’s reported sales trajectory?
Sanofi’s public financial reporting showed only limited sales after launch. Reported figures varied by reporting currency and product presentation, but annual sales remained in the low tens of millions of euros or below.
| Period |
Approximate reported commercial status |
| 2013 |
Initial U.S. launch; low single-digit to low tens of millions in sales |
| 2014 |
Peak commercial period; approximately €10 million to €15 million in reported sales |
| 2015 |
Decline or stagnation as competitive pressure increased |
| 2016 |
Sales fell to a low level; Sanofi reduced strategic commitment |
| 2017-2018 |
Minimal commercial contribution and declining availability |
| 2019 |
Commercial withdrawal and regulatory withdrawal process |
Kynamro never approached blockbuster economics. Its revenue contribution was immaterial to Sanofi, whose business was diversified across diabetes, vaccines, immunology, rare disease, and consumer health. For Ionis, the financial significance was greater at the partnership level because the program generated milestone and royalty opportunities, but the product did not become a meaningful recurring royalty asset.
Sanofi and Ionis reported the program’s commercial underperformance through discontinued development, returned rights, and the eventual termination of commercial activity. Ionis’s later commercial success came from other antisense products, including Spinraza and Tegsedi, rather than mipomersen. (Ionis Pharmaceuticals, 2017, 2018)
Why did mipomersen sodium underperform commercially?
Mipomersen faced a combination of market, clinical, and product-design problems.
How did safety and tolerability affect adoption?
The most important product-level barrier was hepatic tolerability. Mipomersen was associated with increases in alanine aminotransferase and aspartate aminotransferase and with hepatic fat accumulation. The FDA label required liver monitoring and imposed restrictions on use in patients with clinically significant liver disease.
Injection-site reactions were also frequent. In a chronic therapy for a rare disease, a weekly injection can be acceptable when efficacy is strong and alternatives are limited. Mipomersen’s LDL reduction was meaningful but not clearly superior to competing treatments, which weakened its value proposition.
The drug did not establish a cardiovascular-outcome advantage before commercial discontinuation. That left physicians and payers evaluating an expensive therapy on biomarker reduction, tolerability, and practical use rather than on demonstrated event reduction.
How did competing medicines affect Kynamro?
Mipomersen entered a market already containing specialized treatments and soon faced newer options.
| Competitor |
Mechanism |
Key market effect |
| Juxtapid, lomitapide |
Microsomal triglyceride transfer protein inhibitor |
Approved for HoFH before Kynamro; provided an oral alternative |
| Repatha, evolocumab |
PCSK9 monoclonal antibody |
Expanded LDL-lowering options from 2015 |
| Praluent, alirocumab |
PCSK9 monoclonal antibody |
Increased competition in severe hypercholesterolemia |
| LDL apheresis |
Extracorporeal LDL removal |
Established option for severe disease |
| High-intensity statins and ezetimibe |
Conventional lipid lowering |
Used as background therapy |
Lomitapide also carried substantial hepatic and gastrointestinal concerns, but it had oral administration and a clear HoFH positioning. PCSK9 inhibitors later offered simpler administration and broader physician familiarity. The arrival of these products reduced the strategic rationale for a weekly antisense injection with liver-monitoring requirements.
What was the FDA regulatory status of Kynamro?
The FDA approved Kynamro under an orphan-disease framework with a restricted indication. It was subject to postmarketing requirements and safety monitoring. The product was not converted into a broad dyslipidemia indication.
The FDA later withdrew approval at the sponsor’s request. The withdrawal was classified as being for reasons unrelated to safety or effectiveness, according to the Federal Register notice and FDA drug-approval records. The commercial withdrawal reflected the product’s weak market performance and Sanofi’s decision to stop supporting the product.
| Regulatory milestone |
Date or status |
| FDA approval |
January 29, 2013 |
| U.S. launch |
2013 |
| European development |
No sustained commercial authorization |
| Sanofi commercial retrenchment |
Mid-to-late 2010s |
| U.S. commercial availability |
Discontinued |
| FDA approval |
Subsequently withdrawn at sponsor request |
The regulatory history matters because Kynamro was not removed after a finding that it lacked efficacy or had an unacceptable risk-benefit profile in its approved indication. The commercial outcome was driven by economics and competitive positioning.
What patents protected mipomersen sodium?
Mipomersen’s intellectual-property estate was built around antisense oligonucleotide sequences, apoB-100 targeting, compositions, formulations, and treatment methods. Ionis, then Isis Pharmaceuticals, developed much of the underlying antisense technology and licensed commercial rights to Genzyme.
The effective exclusivity position included several layers:
- Composition and sequence claims covering antisense oligonucleotides targeting apoB-100.
- Use claims for reducing apoB-100, LDL cholesterol, or atherogenic lipoproteins.
- Formulation and pharmaceutical-composition claims.
- Orphan-drug exclusivity associated with the HoFH indication.
- Regulatory exclusivity linked to the FDA approval.
Patent protection was less important to the commercial outcome than the small patient population and product limitations. Even a strong patent estate could not create demand where physicians and payers had more convenient alternatives.
When did mipomersen lose exclusivity?
Mipomersen received U.S. orphan-drug exclusivity for the approved HoFH indication. Orphan exclusivity generally lasts seven years from approval, placing the expected statutory period around January 2020, subject to the specific scope of the indication and regulatory status.
The drug also benefited from the Hatch-Waxman framework applicable to an FDA-approved small-molecule drug, although mipomersen’s oligonucleotide structure and narrow market reduced the commercial attractiveness of a generic challenge. The practical loss of market exclusivity was overtaken by withdrawal and discontinuation.
Public Orange Book records and patent databases should be read together because listed patents, patent-term adjustments, pediatric extensions, and product withdrawal can affect the practical timing of an abbreviated new drug application. The commercial relevance of any remaining patent term became limited once Sanofi stopped marketing the product.
Were there Paragraph IV challenges to Kynamro?
No material, widely reported Paragraph IV litigation became a major commercial event for Kynamro. The product’s small market, high development complexity, and eventual withdrawal reduced the incentive for generic manufacturers to pursue a challenge.
A generic applicant would have faced several commercial barriers:
- Very limited patient volume.
- Complex antisense-drug manufacturing.
- Potential difficulty demonstrating sameness and bioequivalence.
- Narrow reimbursement opportunity.
- A market already served by alternative HoFH therapies.
- The prospect that the reference product could be withdrawn before launch.
The absence of visible Paragraph IV litigation should not be interpreted as proof that every patent claim was unassailable. It is better understood as evidence that expected generic returns were unattractive.
What manufacturing and intellectual-property barriers affected mipomersen?
Mipomersen is a chemically synthesized antisense oligonucleotide rather than a conventional tablet molecule. Manufacturing requires control of sequence identity, purity, chemical modifications, impurities, conjugation or backbone chemistry, and analytical characterization.
These requirements create barriers that are different from those for standard small-molecule generics. A competitor must reproduce the active oligonucleotide and satisfy regulatory expectations for quality, pharmacokinetics, immunogenicity, and clinical performance. The manufacturing process itself may also be protected by platform patents, process know-how, and trade secrets.
The relevant competitive barrier was therefore a combination of patents and technical execution. The barrier was meaningful but not sufficient to preserve a profitable market after commercial withdrawal.
Did Sanofi and Ionis have a licensing deal?
Yes. The program originated with Ionis, formerly Isis Pharmaceuticals, and was developed with Genzyme, which Sanofi acquired in 2011. The collaboration included upfront payments, development and regulatory milestones, and potential royalties or commercial economics for Ionis.
The alliance demonstrated the value of Ionis’s antisense platform to a large pharmaceutical partner, but Kynamro’s product economics were weak. Sanofi eventually reduced its involvement, and rights and responsibilities were returned or otherwise restructured as commercial development ended. Ionis retained the broader value of its antisense technology and redirected resources toward programs with stronger clinical or commercial prospects.
The partnership’s financial return was therefore asymmetric: upfront and milestone economics provided value to Ionis, while sustained product revenue did not justify continued commercial investment by Sanofi.
Which companies challenged Kynamro commercially?
No single generic company became the principal challenger. The main competitive pressure came from branded therapies and established procedures.
Sanofi’s commercial alternatives included products from:
- Aegerion Pharmaceuticals, later acquired by Amryt Pharma, with lomitapide.
- Amgen, with evolocumab.
- Regeneron and Sanofi, with alirocumab.
- Lipid-apheresis providers and specialist centers.
The competitive comparison favored therapies with oral dosing, less frequent injections, broader guideline familiarity, or more flexible use across severe hypercholesterolemia populations. Kynamro’s narrow indication and tolerability profile reduced its ability to defend a premium price.
How strong was the mipomersen patent estate?
The patent estate was technically meaningful but commercially weak in application. Ionis had expertise in antisense chemistry, target selection, sequence design, and oligonucleotide delivery. Those assets could support composition, method-of-use, and manufacturing claims.
Patent strength should be assessed on four dimensions:
| Dimension |
Assessment |
| Core technology |
Strong platform position associated with Ionis antisense chemistry |
| Product-specific protection |
Meaningful, but dependent on claim scope and expiration |
| Regulatory exclusivity |
Strong within the narrow HoFH indication during the orphan period |
| Commercial durability |
Weak because the product was withdrawn before a large generic market developed |
The product’s failure was not primarily an intellectual-property failure. It was a failure to convert technical differentiation into durable prescribing demand and predictable reimbursement.
What generic launch scenarios existed for mipomersen?
There were three practical launch scenarios.
Scenario one: No generic entry
This was the most probable outcome. A generic company would have had to invest in a complex oligonucleotide program for a very small market, with no assurance that the reference product would remain commercially available.
Scenario two: Authorized or partner-supported continuation
A specialty pharmaceutical company could have acquired or licensed the product for a limited HoFH market. Such a strategy would require a lower-cost commercial model, specialist distribution, and continued pharmacovigilance.
Scenario three: Post-withdrawal reintroduction
A company could seek approval through a new regulatory pathway, but this would not be a conventional low-risk generic launch. It would require a commercial sponsor, manufacturing capability, regulatory strategy, and a rationale for treating patients who had alternatives.
No scenario generated a visible, sustained generic market.
How does mipomersen compare with current HoFH treatments?
Mipomersen remains relevant as an example of the commercial limits of antisense therapy in ultra-rare disease. Its mechanism was biologically rational, and the drug lowered LDL cholesterol, but the overall product package was less attractive than competing options.
| Factor |
Mipomersen |
Lomitapide |
PCSK9 inhibitors |
| Administration |
Weekly injection |
Oral |
Infrequent injection |
| HoFH positioning |
Yes |
Yes |
Yes, depending on product and jurisdiction |
| Liver monitoring burden |
Significant |
Significant |
Generally lower |
| Outcome evidence |
No established cardiovascular-outcome benefit before withdrawal |
Limited in HoFH |
Broader cardiovascular evidence for PCSK9 class |
| Commercial status |
Withdrawn |
Commercially available in selected markets |
Commercially established |
| Generic or biosimilar risk |
No material generic market |
Limited near-term generic risk |
Biosimilar risk depends on jurisdiction and product |
Mipomersen is not a biosimilar product, and biosimilar competition is not the applicable regulatory framework. Any future competitor would more likely be evaluated under a small-molecule generic, complex-generic, or full application pathway depending on the product and jurisdiction.
What is the financial outlook for mipomersen sodium?
The financial outlook is effectively closed as a commercial product. Kynamro no longer represents a meaningful revenue asset for Sanofi, and there is no established recurring market supporting generic or branded competition.
The program’s financial trajectory followed five stages:
- Platform validation and partnering: Ionis secured a major pharmaceutical collaboration and milestone opportunity.
- Regulatory approval: FDA approval created a formal commercial pathway for HoFH.
- Weak launch: Patient numbers and prescriptions remained low.
- Competitive erosion: Lomitapide and PCSK9 inhibitors weakened the value proposition.
- Withdrawal: Sanofi ended commercial activity, eliminating future product revenue.
The principal residual value lies in historical clinical data, antisense platform know-how, and lessons for rare-disease commercialization. Those assets belong to the broader Ionis technology portfolio rather than to an active Kynamro revenue stream.
Key Takeaways
- Mipomersen sodium, sold as Kynamro, was FDA-approved in 2013 for HoFH.
- The drug used antisense inhibition of apoB-100 to reduce LDL cholesterol.
- Annual treatment cost was approximately $176,000 at launch.
- Commercial sales remained low, generally in the low tens of millions of euros or below.
- Weekly injections, liver monitoring, hepatic adverse events, and injection-site reactions limited adoption.
- Lomitapide, PCSK9 inhibitors, and LDL apheresis created strong competitive pressure.
- No major Paragraph IV litigation or generic launch materially affected the product.
- The drug was not subject to biosimilar competition because it was not a biologic.
- Orphan exclusivity was expected to run for approximately seven years from the 2013 approval, but commercial withdrawal superseded the practical exclusivity question.
- FDA approval was withdrawn at the sponsor’s request for commercial reasons unrelated to safety or effectiveness.
- Kynamro has no meaningful current revenue trajectory absent a new sponsor and a new commercialization strategy.
FAQs About Mipomersen Sodium Market and Patent Risk
Is mipomersen sodium still available in the United States?
No. Kynamro was commercially discontinued, and the FDA subsequently withdrew the approval at the sponsor’s request.
Did mipomersen sodium become a blockbuster drug?
No. Sales remained far below blockbuster levels because HoFH is an ultra-rare indication and competing therapies offered more attractive treatment profiles.
Is mipomersen sodium a biologic?
No. It is a chemically synthesized antisense oligonucleotide. Biosimilar competition is therefore not the applicable pathway.
Could a company relaunch Kynamro?
A relaunch would require a sponsor to acquire or develop the necessary commercial, manufacturing, regulatory, and pharmacovigilance infrastructure. The small market and competing therapies make the economics difficult.
What was the main reason for Kynamro’s commercial failure?
The central problem was a weak product-market fit: a high-cost weekly injectable with liver-monitoring requirements and tolerability concerns competing against other HoFH treatments with more favorable administration or broader clinical adoption.
References
- Sanofi. (2014). 2014 annual report. https://www.sanofi.com
- Sanofi. (2015). 2015 annual report. https://www.sanofi.com
- Sanofi. (2016). 2016 annual report. https://www.sanofi.com
- Ionis Pharmaceuticals, Inc. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.ionispharma.com
- Ionis Pharmaceuticals, Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.ionispharma.com
- U.S. Food and Drug Administration. (2013). Kynamro prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2019). Kynamro approval and product information. https://www.fda.gov
- U.S. Food and Drug Administration. (2020). Withdrawal of approval of Kynamro, Federal Register notice. https://www.federalregister.gov
- European Medicines Agency. (2012). Mipomersen: withdrawal of application for marketing authorisation. https://www.ema.europa.eu
